Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%

2026-07-13 07:30:00

DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for Dario Dario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data points NEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer ("B2B2C") recurring revenue by approximately 10% to 15% from existing customers, before the impact of future customer wins or additional condition expansions.     While Dario continues to demonstrate success with its land-and-expand strategy with existing enterprise customers through its multi-condition platform, DarioIQ creates an additional opportunity to lift B2B2C annual recurring revenues from current clients.

Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership

2026-07-06 07:30:00

Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell.  This opportunity makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only ("ASO") book of business, representing access to hundreds of thousands of covered lives.

Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy

2026-07-02 08:00:00

Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful

Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy

2026-07-02 07:30:00

Third health plan customer to expand beyond initial deployment, reinforcing Dario's land-and-expand strategy and creating significant opportunity to grow revenue within existing customer base NEW YORK, July 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced that one of the 5 largest health insurers in the U.S. has extended its initial agreement and expanded its relationship with Dario by adding the Company's hypertension solution, following success with Dario's behavioral health offering. The health plan's roll out of Dario's cardiometabolic care significantly increases the addressable population and has the potential to approximately triple Dario's revenue opportunity under this customer relationship.

Dario Appoints Former Humana Chief Compliance Officer Sean O'Reilly to Advisory Board to Support Strategic Growth and Healthcare Partnerships

2026-06-30 07:30:00

O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and providers as Dario moves closer to care O'Reilly's track record of leveraging advanced data analytics and AI in supporting value-based care strongly aligned with Dario's AI transition NEW YORK, June 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-enabled digital health solutions, today announced the appointment of Sean O'Reilly to its Advisory Board. The appointment reflects Dario's continued focus on strengthening its strategic guidance as the Company advances its channel partner-led growth strategy and moves closer to care across the payer, provider and employer markets.

Dario Announces Strategic Collaboration with Beluga Health to Deliver Provider-Backed, Integrated Care at Scale

2026-06-29 07:00:00

Dario's best-in-class, consumer-centric chronic care platform, combined now with Beluga's embedded clinical delivery, extends member engagement to include provider-delivered treatment, lowering costs and expanding value for existing clients while opening large new markets NEW YORK, June 29, 2026 /PRNewswire/ --  DarioHealth Corp.  (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced it has entered into a Collaborative Services Agreement ("Agreement") with Beluga Health, P.A. ("Beluga"), establishing a strategic partnership to deliver a provider-backed, digitally-enabled model for longitudinal care, population health and quality improvement.

DarioHealth (DRIO) Upgraded to Buy: Here's Why

2026-06-17 13:01:26

DarioHealth (DRIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform

2026-06-08 08:00:00

Data from a total of 27 studies presented at ADA over 8 years reinforce Dario's strategic move closer to care, expanding revenue model into claims-based and outcomes-driven payments serving health plans, employers and other enterprise buyers  Weight loss of 6.4% with Dario alone, and 14.3% when combined with a GLP-1 at 12 months, exceeding benchmarks based on medications alone 44.8% of high-risk diabetes users achieved at least a 1% eA1c reduction at 12 months NEW YORK, June 8, 2026 /PRNewswire/ -- DarioHealth Corp.  (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced presentation of four studies at the American Diabetes Association's ("ADA") Scientific Sessions highlighting the clinical and economic value of sustained engagement on its platform across high-risk cardiometabolic populations. Taken together, the studies reinforce a clear commercial message for payers, employers and other enterprise buyers: when high-risk members stay engaged with Dario's platform, outcomes improve in ways that can translate into lower cost of care, stronger member retention and greater long-term value.